22:42 , Apr 24, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Mice implanted with grafts of human brain organoids could be used to study the pathogenesis of neurodevelopmental disorders and screen therapies to treat them. The organoids are generated by: culturing disassociated human...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Regeneron regulatory update

U.S. Patent No. 5,595,904 issued covering the family of MAP2 protein kinases, intracellular enzymes involved in regulating cell growth. REGN is the exclusive licensee to the patent, which issued to the University of Texas Southwestern...
08:00 , Feb 16, 2012 |  BC Innovations  |  Targets & Mechanisms

Steroids not so depressing

Mapreg S.A.S. researchers have shown for the first time in vivo that targeting microtubule-associated protein 2 with steroid derivatives can have an antidepressant effect in mouse models of depression. 1 Indeed, in some of those...
08:00 , Feb 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Microtubule-associated protein 2 (MAP2) Studies in mice identified a pregnenolone derivative that could help treat depression. In a mouse model of depression, 3b-methoxy-pregnenolone (MAP4343)...
08:00 , Feb 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer Keratin 14 (KRT14) Patient sample studies suggest KRT14 could help predict bladder cancer prognosis. In two sets of gene and protein expression data...
07:00 , Mar 24, 2008 |  BC Week In Review  |  Clinical News

MAP4343: Phase I start

Late this year, Mapreg plans to start a Phase I trial. MAP4343 has Orphan Drug designation for the indication in the EU. Mapreg S.A.S. , Paris, France   Product: MAP4343   Business: Neurology   Molecular...
07:00 , Mar 24, 2008 |  BC Week In Review  |  Clinical News

MAP4343 regulatory update

EMEA granted Orphan Drug designation for Mapreg's MAP4343 to treat spinal cord injury. The injectable neurosteroid derivative, which targets microtubule associated protein type 2 ( MAP2 ), will begin Phase I testing this year. Mapreg...